Sermorelin

Historical approved uses; current products require separate evaluation.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone that can stimulate pituitary growth-hormone secretion. It has a history of approved diagnostic and pediatric uses, but that history does not establish contemporary wellness claims. [1]

02 Potential benefits

Mimics the first 29 amino acids of GHRH. Can stimulate pituitary growth-hormone release. [1]

03 Evidence & its limits

The 2013 determination explains why historical products left the market; it does not newly approve a present-day compounded product. Diagnostic hormone responses and pediatric growth outcomes cannot, by themselves, demonstrate anti-aging or body-composition benefits in adults. [1]

04 Risks & unknowns

Geref approvals were withdrawn effective June 18, 2009. In 2013 FDA determined the products were not withdrawn for safety or effectiveness reasons. Contemporary wellness claims are not established by its historical diagnostic and pediatric growth-failure indications. [1]

05 Status & scope

It has a history of approved diagnostic and pediatric uses, but that history does not establish contemporary wellness claims. Geref approvals were withdrawn effective June 18, 2009. In 2013 FDA determined the products were not withdrawn for safety or effectiveness reasons. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates

[2] FDA determination on withdrawn Geref products, March 4, 2013

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.